|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's range||0.0323 - 0.0326|
|52-week range||0.0251 - 0.1250|
|Beta (5Y monthly)||0.96|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Elixinol, hemp-derived CBD brand and industry veteran, announced today the launch of two new innovative CBD products focused on supporting sleep*. Elixinol's Sleep Rapid Rest Liposome and Sleep Gummies are unique, melatonin-free options for consumers to support optimal sleep. Both products include CBN, marking a first for the brand to include a minor cannabinoid into product formulations. The new product additions also coincide with the brand's new '2022 & You' wellness campaign, encouraging con
Elixinol Wellness Limited (Elixinol or the Company) (ASX:EXL; OTCQB:ELLXF) is pleased to communicate that Assembly Bill 45 (AB45) was signed into law by Californian Governor, Mr Gavin Newsom on 6 October 2021, establishing a comprehensive regulatory framework for the manufacture and retail sale of products in California containing hemp derived cannabidiol (CBD), including dietary supplements, topicals, over-the-counter, and pet products, among others.
Elixinol, a global hemp-derived CBD brand and industry veteran, introduced its first line of pet products. The new collection is specifically formulated for dogs and includes a bacon-flavored tincture and two functionally focused CBD dog chews targeting specific benefits. The collection is available now on Elixinol.com.